The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 579-587

  Seaber, E ^a   On, N ^a   Dixon, R M ^a,b   Gibbens, M ^a   Leavens, W J ^a   Liptrot, J ^a   Chittick, G ^a   Posner, J ^a   Rolan, P E ^a,c   Peck, R W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

311C90; Bioavailability; Ge nder; Metabolism; Pharmacokinetics; Radiolabel; Zolmitriptan

Indexed keywords

ZOLMITRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIGRAINE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 8544267195     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00614.x     Document Type: Article

References (13)

1. 1D receptor agonist 311C90. New advances in Headache Research 1994; 4: 3-4.
2. Humphrey P, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-445.
3. Moskowitz NA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-311.
4. Kaube H, Hoskin K, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-792.
5. Goadsby PJ, Edvinsson L. Central and peripheral trigeminovascular activation in the cat is inhibited by the novel 5HT-1D agonist 311C90. Headache 1994; 34: 394-399.
6. 1D agonist in the acute treatment of migraine. An overview of efficacy. Cephalalgia 1995; 15(suppl 14): 217.
7. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996; 36(suppl 2): 4-7.
8. Seaber E, On N, Dixon R, Phillips S, Posner J, Rolan P. The pharmacokinetics and tolerability of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996; 41: 141-147.
9. Peck R, Dixon R, Seaber E, On N, Mercer J, Posner J, Rolan PE. Clinical Pharmacology of 311C90. In Proceedings of the 10th Migraine Trust Symposium, F. Clifford Rose ed. New advances in Headache Research: 4 London: Smith-Gordon 1994: 9-10.
10. Humphrey PPA, Fenuik W, Marriot AS, Tanner RJM, Jackson MR, Tucker ML. Pre-clinical studies on the antimigraine drug, sumatriptan. Eur Neurol 1991; 31: 282-290.
11. Lacey LF, Hussey EK, Fowler PA. The single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 543-548.
12. Gibaldi M. Pharmacokinetic variability, body weight, age, sex and genetic factors. In Biopharmaceutics and Clinical Pharmacokinetics 1984, 3rd edition, Lea of Febiger, Philadelphia: 206-277.
13. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-294.